Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) Revenue growth
Charles River Laboratories International, Inc.'s revenue growth over the twelve months to 30 June 2026 was −0.74%, up 0.1 percentage points from fiscal 2025 (−0.85%). Over the past ten years it has ranged from −1.92% (fiscal 2024) to 23.3% (fiscal 2016); the current reading is higher than 18% of that period. That is below the Diagnostics & Research industry median of 7.69% and below the Healthcare sector median of 8.27%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −0.85% | 1.07 |
| FY2024 | −1.92% | (5.78) |
| FY2023 | 3.86% | (8.45) |
| FY2022 | 12.3% | (8.77) |
| FY2021 | 21.1% | 9.53 |
| FY2020 | 11.6% | (4.12) |
| FY2019 | 15.7% | (6.32) |
| FY2018 | 22.0% | 11.51 |
| FY2017 | 10.5% | (12.86) |
| FY2016 | 23.3% | 18.28 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −2.72% | (3.90) |
| Mar 2026 | 1.18% | 2.01 |
| Dec 2025 | −0.83% | (0.34) |
| Sep 2025 | −0.49% | (1.08) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| GH Guardant Health, Inc. compare | 42.7% |
| MEDP Medpace Holdings, Inc. compare | 24.7% |
| TWST Twist Bioscience Corporation compare | 19.2% |
| DGX Quest Diagnostics Incorporated compare | 9.87% |
| LH Labcorp Holdings Inc. compare | 6.41% |
| RVTY Revvity Inc. compare | 4.05% |
| ICLR ICON PLC compare | 3.26% |
| QGEN QIAGEN N.V. compare | 2.96% |
| CRL Charles River Laboratories International, Inc. | −0.74% |
| Diagnostics & Research industry median | 7.69% |
| Healthcare sector median | 8.27% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement